Cargando…

Acquisition of a Stable and Transferable bla (NDM-5)-Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing Klebsiella pneumoniae During Treatment

The emergence and prevalence of carbapenem-resistant Enterobacteriaceae (CRE) have drawn worldwide attention. Ceftazidime/avibactam (CAZ/AVI) gives us a valuable alternative strategy to treat CRE infections. Unfortunately, CAZ/AVI resistance could occur during CAZ/AVI treatment. The CAZ/AVI-resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jiangqing, Zhang, Shengcen, Zhao, Zhichang, Chen, Min, Cao, Yingping, Li, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329419/
https://www.ncbi.nlm.nih.gov/pubmed/34354959
http://dx.doi.org/10.3389/fcimb.2021.658070
_version_ 1783732499394854912
author Huang, Jiangqing
Zhang, Shengcen
Zhao, Zhichang
Chen, Min
Cao, Yingping
Li, Bin
author_facet Huang, Jiangqing
Zhang, Shengcen
Zhao, Zhichang
Chen, Min
Cao, Yingping
Li, Bin
author_sort Huang, Jiangqing
collection PubMed
description The emergence and prevalence of carbapenem-resistant Enterobacteriaceae (CRE) have drawn worldwide attention. Ceftazidime/avibactam (CAZ/AVI) gives us a valuable alternative strategy to treat CRE infections. Unfortunately, CAZ/AVI resistance could occur during CAZ/AVI treatment. The CAZ/AVI-resistant Carbapenem-resistant Klebsiella pneumoniae (CR-KP) (KP137060) and earlier CAZ/AVI-susceptible isolate (KP135194) from the same hospitalized patient were collected at Fujian Medical University Union Hospital between October and November 2019. In this study, CAZ/AVI MICs of CAZ/AVI-susceptible and -resistant isolates (KP135194 and KP137060) were 4 mg/L and 128 mg/L, respectively; and the two isolates had the same antibiotic resistance pattern to other carbapenems. Two strains were then submitted for whole-genome sequencing and bioinformatic analysis. ompK36 was not detected in two isolates. No mutation was observed in bla (KPC-2), ompK35 and ompK37 in this study and there was no significant difference of the expression in bla (KPC-2), ompK35 and ompK37 between the two isolates (p>0.05). Two isolates were sequence type 11 and harbored bla (KPC-2), bla (SHV-182) and bla (TEM-1B). Compared with KP135194, KP137060 harbored an additional bla (NDM-5) positive plasmid. bla (NDM-5) gene could be successfully transferred into E. coli J53 at a conjugation frequency of 1.14×10(-4). Plasmid stability testing showed that bla (KPC-2)- and bla (NDM-5)-harboring plasmids were still stably maintained in the hosts. Growth assay and growth competition experiments showed there was no significant difference in fitness cost between two CR-KP isolates. Our study described the acquisition of a bla (NDM-5)-harboring plasmid leading to resistance to ceftazidime/avibactam in KPC-2-producing Klebsiella pneumoniae during treatment. This phenomenon deserves further exploration.
format Online
Article
Text
id pubmed-8329419
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83294192021-08-04 Acquisition of a Stable and Transferable bla (NDM-5)-Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing Klebsiella pneumoniae During Treatment Huang, Jiangqing Zhang, Shengcen Zhao, Zhichang Chen, Min Cao, Yingping Li, Bin Front Cell Infect Microbiol Cellular and Infection Microbiology The emergence and prevalence of carbapenem-resistant Enterobacteriaceae (CRE) have drawn worldwide attention. Ceftazidime/avibactam (CAZ/AVI) gives us a valuable alternative strategy to treat CRE infections. Unfortunately, CAZ/AVI resistance could occur during CAZ/AVI treatment. The CAZ/AVI-resistant Carbapenem-resistant Klebsiella pneumoniae (CR-KP) (KP137060) and earlier CAZ/AVI-susceptible isolate (KP135194) from the same hospitalized patient were collected at Fujian Medical University Union Hospital between October and November 2019. In this study, CAZ/AVI MICs of CAZ/AVI-susceptible and -resistant isolates (KP135194 and KP137060) were 4 mg/L and 128 mg/L, respectively; and the two isolates had the same antibiotic resistance pattern to other carbapenems. Two strains were then submitted for whole-genome sequencing and bioinformatic analysis. ompK36 was not detected in two isolates. No mutation was observed in bla (KPC-2), ompK35 and ompK37 in this study and there was no significant difference of the expression in bla (KPC-2), ompK35 and ompK37 between the two isolates (p>0.05). Two isolates were sequence type 11 and harbored bla (KPC-2), bla (SHV-182) and bla (TEM-1B). Compared with KP135194, KP137060 harbored an additional bla (NDM-5) positive plasmid. bla (NDM-5) gene could be successfully transferred into E. coli J53 at a conjugation frequency of 1.14×10(-4). Plasmid stability testing showed that bla (KPC-2)- and bla (NDM-5)-harboring plasmids were still stably maintained in the hosts. Growth assay and growth competition experiments showed there was no significant difference in fitness cost between two CR-KP isolates. Our study described the acquisition of a bla (NDM-5)-harboring plasmid leading to resistance to ceftazidime/avibactam in KPC-2-producing Klebsiella pneumoniae during treatment. This phenomenon deserves further exploration. Frontiers Media S.A. 2021-07-20 /pmc/articles/PMC8329419/ /pubmed/34354959 http://dx.doi.org/10.3389/fcimb.2021.658070 Text en Copyright © 2021 Huang, Zhang, Zhao, Chen, Cao and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Huang, Jiangqing
Zhang, Shengcen
Zhao, Zhichang
Chen, Min
Cao, Yingping
Li, Bin
Acquisition of a Stable and Transferable bla (NDM-5)-Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing Klebsiella pneumoniae During Treatment
title Acquisition of a Stable and Transferable bla (NDM-5)-Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing Klebsiella pneumoniae During Treatment
title_full Acquisition of a Stable and Transferable bla (NDM-5)-Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing Klebsiella pneumoniae During Treatment
title_fullStr Acquisition of a Stable and Transferable bla (NDM-5)-Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing Klebsiella pneumoniae During Treatment
title_full_unstemmed Acquisition of a Stable and Transferable bla (NDM-5)-Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing Klebsiella pneumoniae During Treatment
title_short Acquisition of a Stable and Transferable bla (NDM-5)-Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing Klebsiella pneumoniae During Treatment
title_sort acquisition of a stable and transferable bla (ndm-5)-positive plasmid with low fitness cost leading to ceftazidime/avibactam resistance in kpc-2-producing klebsiella pneumoniae during treatment
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329419/
https://www.ncbi.nlm.nih.gov/pubmed/34354959
http://dx.doi.org/10.3389/fcimb.2021.658070
work_keys_str_mv AT huangjiangqing acquisitionofastableandtransferableblandm5positiveplasmidwithlowfitnesscostleadingtoceftazidimeavibactamresistanceinkpc2producingklebsiellapneumoniaeduringtreatment
AT zhangshengcen acquisitionofastableandtransferableblandm5positiveplasmidwithlowfitnesscostleadingtoceftazidimeavibactamresistanceinkpc2producingklebsiellapneumoniaeduringtreatment
AT zhaozhichang acquisitionofastableandtransferableblandm5positiveplasmidwithlowfitnesscostleadingtoceftazidimeavibactamresistanceinkpc2producingklebsiellapneumoniaeduringtreatment
AT chenmin acquisitionofastableandtransferableblandm5positiveplasmidwithlowfitnesscostleadingtoceftazidimeavibactamresistanceinkpc2producingklebsiellapneumoniaeduringtreatment
AT caoyingping acquisitionofastableandtransferableblandm5positiveplasmidwithlowfitnesscostleadingtoceftazidimeavibactamresistanceinkpc2producingklebsiellapneumoniaeduringtreatment
AT libin acquisitionofastableandtransferableblandm5positiveplasmidwithlowfitnesscostleadingtoceftazidimeavibactamresistanceinkpc2producingklebsiellapneumoniaeduringtreatment